Challenger Wealth Management Buys Shares of 7,925 Pfizer Inc. (NYSE:PFE)

Challenger Wealth Management purchased a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 7,925 shares of the biopharmaceutical company’s stock, valued at approximately $210,000.

Several other large investors have also recently made changes to their positions in the stock. Tallon Kerry Patrick purchased a new stake in Pfizer during the fourth quarter valued at approximately $509,000. Brighton Jones LLC increased its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. CX Institutional lifted its holdings in shares of Pfizer by 9.1% during the 4th quarter. CX Institutional now owns 50,390 shares of the biopharmaceutical company’s stock valued at $1,337,000 after purchasing an additional 4,183 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in shares of Pfizer by 10.2% in the 4th quarter. Exchange Traded Concepts LLC now owns 76,250 shares of the biopharmaceutical company’s stock worth $2,023,000 after purchasing an additional 7,072 shares in the last quarter. Finally, Curated Wealth Partners LLC grew its stake in Pfizer by 25.6% during the 4th quarter. Curated Wealth Partners LLC now owns 45,337 shares of the biopharmaceutical company’s stock worth $1,203,000 after buying an additional 9,236 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 1.3%

NYSE:PFE opened at $23.33 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s fifty day moving average price is $23.38 and its 200-day moving average price is $25.17. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm has a market capitalization of $132.66 billion, a P/E ratio of 16.55, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the firm earned $0.82 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.37%. The ex-dividend date is Friday, May 9th. Pfizer’s payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on PFE shares. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. Finally, Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.